Smajkic A, Weine S, Djuric-Bijedic Z, Boskailo E, Lewis J, Pavkovic I
The Project on Genocide, Psychiatry and Witnessing, Department of Psychiatry, University of Illinois at Chicago, and Chicago Health Outreach, Heartland Alliance, 60612-7327, USA.
J Trauma Stress. 2001 Jul;14(3):445-52. doi: 10.1023/A:1011177420069.
Three new antidepressants were used in treating posttraumatic stress disorder (PTSD) and symptoms of depression in Bosnian refugees. Thirty-two Bosnian refugees seeking treatment at a mental health clinic participated in a case series study. All received open trials of Sertraline (n = 15), Paroxetine (n = 12), or Venlafaxine (n = 5), with standard clinical doses. Overall, Sertraline and Paroxetine produced statistically significant improvement at 6 weeks in PTSD symptom severity in depression, and in Global Assessment of Functioning. Venlafaxine produced improvement in PTSD symptom severity and in Global Assessment of Functioning, did not yield improvement in symptoms of major depressive disorder; and had a high rate of side effects. Notwithstanding improvement of symptoms, all 32 refugees remained PTSD positive at the diagnostic level at the 6-week follow-up.
三种新型抗抑郁药被用于治疗波斯尼亚难民的创伤后应激障碍（PTSD）和抑郁症状。32名在心理健康诊所寻求治疗的波斯尼亚难民参与了一项病例系列研究。所有人均接受了舍曲林（n = 15）、帕罗西汀（n = 12）或文拉法辛（n = 5）的开放试验，采用标准临床剂量。总体而言，舍曲林和帕罗西汀在6周时使PTSD症状严重程度、抑郁及总体功能评估方面产生了具有统计学意义的改善。文拉法辛使PTSD症状严重程度和总体功能评估有所改善，但未使重度抑郁症症状得到改善，且副作用发生率较高。尽管症状有所改善，但在6周随访时，所有32名难民在诊断层面上仍为PTSD阳性。
